| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11571398 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
| US11241400 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
| US11464752 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
| US11090278 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
| US11478436 | NEXUS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(16 years from now) | |
Emerphed is owned by Nexus.
Emerphed contains Ephedrine Sulfate.
Emerphed has a total of 5 drug patents out of which 0 drug patents have expired.
Emerphed was authorised for market use on 28 February, 2023.
Emerphed is available in solution;intravenous dosage forms.
Emerphed can be used as use of ephedrine sulfate for treating hypotension.
The generics of Emerphed are possible to be released after 16 May, 2040.
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 28 February, 2023
Treatment: Use of ephedrine sulfate for treating hypotension
Dosage: SOLUTION;INTRAVENOUS
How can I launch a generic of EMERPHED before it's drug patent expiration?
More Information on Dosage
EMERPHED family patents
